Rundle Charles H, Chen Shin-Tai, Coen Michael J, Wergedal Jon E, Stiffel Virginia, Lau Kin-Hing William
Musculoskeletal Disease Center, J. L. Pettis Memorial VA Medical Center, Loma Linda, California, United States of America; Department of Medicine, Loma Linda University School of Medicine, Loma Linda, California, United State of America.
Musculoskeletal Disease Center, J. L. Pettis Memorial VA Medical Center, Loma Linda, California, United States of America; Department of Medicine, Loma Linda University School of Medicine, Loma Linda, California, United State of America; Department of Biochemistry, Loma Linda University School of Medicine, Loma Linda, California, United State of America.
PLoS One. 2014 May 21;9(5):e98004. doi: 10.1371/journal.pone.0098004. eCollection 2014.
This study sought to determine if direct application of the lentiviral (LV)-cyclooxygenase 2 (COX2) vector to the tendon-bone interface would promote osteointegration of the tendon graft in a rat model of biceps tenodesis. The LV-COX2 gene transfer strategy was chosen for investigation because a similar COX2 gene transfer strategy promoted bony bridging of the fracture gap during bone repair, which involves similar histologic transitions that occur in osteointegration. Briefly, a 1.14-mm diameter tunnel was drilled in the mid-groove of the humerus of adult Fischer 344 rats. The LV-COX2 or βgal control vector was applied directly into the bone tunnel and onto the end of the tendon graft, which was then pulled into the bone tunnel. A poly-L-lactide pin was press-fitted into the tunnel as interference fixation. Animals were sacrificed at 3, 5, or 8 weeks for histology analysis of osteointegration. The LV-COX2 gene transfer strategy enhanced neo-chondrogenesis at the tendon-bone interface but with only marginal effect on de novo bone formation. The tendon-bone interface of the LV-COX2-treated tenodesis showed the well-defined tendon-to-fibrocartilage-to-bone histologic transitions that are indicative of osteointegration of the tendon graft. The LV-COX2 in vivo gene transfer strategy also significantly enhanced angiogenesis at the tendon-bone interface. To determine if the increased osteointegration was translated into an improved pull-out mechanical strength property, the pull-out tensile strength of the LV-COX2-treated tendon grafts was determined with a pull-out mechanical testing assay. The LV-COX2 strategy yielded a significant improvement in the return of the pull-out strength of the tendon graft after 8 weeks. In conclusion, the COX2-based in vivo gene transfer strategy enhanced angiogenesis, osteointegration and improved return of the pull-out strength of the tendon graft. Thus, this strategy has great potential to be developed into an effective therapy to promote tendon-to-bone healing after tenodesis or related surgeries.
本研究旨在确定在大鼠二头肌肌腱固定模型中,将慢病毒(LV)-环氧化酶2(COX2)载体直接应用于肌腱-骨界面是否会促进肌腱移植物的骨整合。选择LV-COX2基因转移策略进行研究,是因为类似的COX2基因转移策略在骨修复过程中促进了骨折间隙的骨桥形成,而骨修复涉及与骨整合中发生的类似组织学转变。简而言之,在成年Fischer 344大鼠肱骨的中沟钻一个直径1.14毫米的隧道。将LV-COX2或β半乳糖苷酶对照载体直接应用于骨隧道和肌腱移植物的末端,然后将肌腱移植物拉入骨隧道。将聚-L-丙交酯销压配合到隧道中作为干涉固定。在3、5或8周时处死动物,进行骨整合的组织学分析。LV-COX2基因转移策略增强了肌腱-骨界面的新软骨形成,但对新生骨形成的影响很小。LV-COX2处理的肌腱固定的肌腱-骨界面显示出明确的肌腱到纤维软骨到骨的组织学转变,这表明肌腱移植物发生了骨整合。LV-COX2体内基因转移策略也显著增强了肌腱-骨界面的血管生成。为了确定增加的骨整合是否转化为改善的拔出机械强度特性,用拔出机械测试法测定LV-COX2处理的肌腱移植物的拔出拉伸强度。LV-COX2策略在8周后显著改善了肌腱移植物的拔出强度恢复。总之,基于COX2的体内基因转移策略增强了血管生成、骨整合,并改善了肌腱移植物的拔出强度恢复。因此,该策略具有很大的潜力,可发展成为一种有效的治疗方法,以促进肌腱固定或相关手术后的肌腱-骨愈合。